R&D News | pharmaphorum

News

Home

Sunbird, Glympse merge for earlier diagnosis of Alzheimer’s

Biotech Sunbird Bio has announced its completed merger with Glympse Bio, which it is hoped will accelerate development of the companies’ protein-based diagnostic technolog

News

Regeneron dials up in gene therapy with Decibel deal

Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a

News

eureKING buys SCTbio to extend biomanufacturing push

Special purpose acquisition company (SPAC) eureKING has agreed a deal to buy SCTbio as part of a plan to build a contract manufacturing company specialising in biologic th

News

Novartis gets a win in chronic hives, setting up filings

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a su

News

Arcus and Gilead drop A2R drug for prostate cancer

Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an

News

Bayer pulls plug on respiratory drug PEG-ADM

Bayer revealed in its second-quarter results update this morning that it has stopped the development of adrenomedullin pegol (PEG-ADM), which had reached phase 2 for the t

Sunbird, Glympse merge for earlier diagnosis of Alzheimer’s

Regeneron dials up in gene therapy with Decibel deal

eureKING buys SCTbio to extend biomanufacturing push

Novartis gets a win in chronic hives, setting up filings

Arcus and Gilead drop A2R drug for prostate cancer

Bayer pulls plug on respiratory drug PEG-ADM

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks